Yet, these results suggest that MASTL inhibition may contribute to the reactivation of PP2A in specific tumor types, an attractive possibility given the relevance of PP2A activation as a therapeutic strategy in cancer [26]. The gene discussed is MASTL; the disease is neoplasm.